Fig. 3

Immunogenic SEPs of R. akari. (a) R. akari proteins (140 μg) from whole-cell extract separated by 2-DE. 1- OmpB (A8GPL7), 2 - chaperon protein DnaK (A8GMF9), 3–60 kDa chaperonin GroEL (A8GPB6), 4–44 kDa uncharacterized protein (A8GP63), 5 – peptidoglycan associated lipoprotein (A8GPW0), 6 – superoxide dismutase (A8GNP0) (b) 2-D Western blot analysis of R. akari proteins using serum from infected rabbit (1:1000) (c) or infected patient’s serum (1:1000) (d) SDS-PAGE of selected SEPs prepared with recombinant technology. L: protein marker; lane 1–44 kDa uncharacterized protein (A8GP63) (3 μg); 2–60 kDa chaperonin GroEL (8 μg); 3- chaperon protein DnaK (6 μg). (e) Western blot analyses of recombinant (2 μg per lane) 44 kDa uncharacterized protein (lanes 1–7), 60 kDa chaperonin GroEL (lanes 8–14), and chaperon protein DnaK (lanes 15–21) probed against - 1-2, 8–9, 15–16: sera of healthy donors (negative controls, 1:1000); 3–5, 10–12, 17–19: sera of Rickettsialpox patients (1:1000), and 6–7, 13–14, 20–21: sera of patients with SFG rickettsial infection (1:1000)